ABIONYX Pharma in talks for a strategic partnership in sepsis

ABIONYX Pharma, a biotechnology company specializing in innovative therapies, announced on August 27, 2025, the opening of discussions with a major player in the healthcare sector on sepsis. This proposed collaboration aims to accelerate the development and deployment of CER-001, a potential treatment for sepsis.

This partner, recognized for its influence in the sector, is exploring the possibilities of a strategic alliance with ABIONYX to benefit from its cutting-edge technology. These discussions mark an important milestone for the company, highlighting the growing interest in its technological approach to the treatment of sepsis.